Determination of spectrophotometric protonation constant of cholinesterase inhibitors

Yıl 2017, Cilt: 1 Sayı: 1, 7 - 13, 17.10.2017

Yaşar Doğan Daldal Ebru Çubuk Demiralay Güleren Alsancak

https://doi.org/10.32571/ijct.335934

Cited By: 3

Öz

The protonation constant (pK_a) of rivastigmine, galantamine and
donepezil which are cholinesterase inhibitors used in cure of Alzheimer's disease in acetonitrile-water binary
mixtures were determined at 25 ^oC in ionic strength by
spectrophotometric method. Spectra of the drugs were recorded with 1 nm
resolution over the 200 to 400 nm interval. Data assessment was carried out with the STAR software program to calculate molar
absorbances and stability constants of the compounds studied. Aqueous protonation constant of these compounds were calculated from
determined through linear  relationship between the mole fraction of
acetonitrile and the pK_a values and the Yasuda-Shedlovsky equality. The pK_a values
of inhibitors at 25°C were converted to values at 37°C, without extra
estimation. The predicted and calculated pK_a values were compared with literature values.

Anahtar Kelimeler

Cholinesterase Inhibitors, Protonation Constant, UV-VIS Spectrophotometry, Solute Descriptors

Kaynakça

• 1. Nordberg, A.; Svensson, A.L. Drug Saf. 1998, 19(6), 465-480.
• 2. Thompson, P.A.; Wright, D.E.; Counsell, C.E.; Zajicek, J. Int. Psychogeriatr. 2012, 24(5), 689-697.
• 3. Demiralay, E.C.; Alsancak, G.; Ozkan, S.A. J. Sep. Sci. 2009, 32, 2928 - 2936.
• 4. Yılmaz, H.; Demiralay,E.C. J. Liq. Chromatogr. Relat. Technol. 2015, 38(1), 97-103.
• 5. Babič, S.; Horvat, A.J.M.; Pavlović, D.; Kaštelan Macan, M. Trends Analyt. Chem. 2007, 26(11), 1043-1061.
• 6. Talay, A.; Demiralay, E.C.; Daldal, Y.D.; Üstün, Z.J. Mol. Liq. 2015, 208, 286-290.
• 7. Tam, K.Y.; Hadley, M.; Patterson, W. Talanta 1999, 49, 539-546.
• 8. Tam, K.Y.; Takács-Novák, K. Anal. Chim. Acta 2001, 434, 157-167.
• 9. Sanli, S.; Altun, Y.; Guven, G. J. Chem. Eng. Data 2014, 59, 4015-4020.
• 10. Daldal, Y.D.; Çakır, C.; Yılmaz, H.; Demiralay, E.C.; Özkan, S.A.; Alsancak, G. Curr. Drug. Ther. 2014, 9, 277-284.
• 11. Sun, N.; Avdeef, A. J. Pharm. Biomed. Anal. 2011, 56, 173-182.
• 12. Narasimham, L.; Dnyandeo Barhate, V. Eur. J. Chem, 2011, 2 (1), 36-46.
• 13. Sanli, N.; Sanli, S.; Sızır, U.; Gumustas, M., Ozkan, S.A. Chromatographia 2011, 73(11-12), 1171-1176.
• 14. Canbay, H.S.; Demiralay, E.C.; Alsancak, G.; Ozkan, S.A. J. Chem. Eng. Data 2011, 56(5), 2071-2076.
• 15. Yasuda, M. Bull. Chem. Soc. Jpn. 1959, 32, 429-432.
• 16. Shedlovsky, T. Electrolytes, in: B. Peasce (Ed.), Pergamon Press, New York, 1962.
• 17. Marvin Sketch program, Chemaxon, http://www.chemaxon.com, (accessed 2016).
• 18. Rondinini, S.; Mussini, P.R.; Mussini, T. Pure Appl. Chem. 1987, 59, 1549-1560.
• 19. Beltran, J.L.; Codony, R.; Prat, M.D. Anal. Chim. Acta 1993, 276, 441-454.
• 20. Daldal, Y.D.; Demiralay, E.C.; Ozkan, S.A. J. Braz. Chem. Soc. 2016, 27(3), 493-499.
• 21. NLREG Version 4.0. P.H. Sherrod. http://www.sandh.com/Sherrod, (accessed 1991).
• 22. Uysal, R.; Daldal, Y.D.; Üstün, Z.; Demiralay, E.C. Eurasian J. Anal. Chem. 2017, 12(1), 23-43.
• 23. Meloun, M.; Bordovská, S.; Galla, L. SRX Pharmacol. 2010, 2010, 1-14.
• 24. Hsieh, Y.H.; Yang, Y.H.; Yeh, H.H.; Lin, P.C.; Chen, S.H. Electrophoresis 2009, 30(4), 644-653.
• 25. Luan, F.; Ma, W.; Zhang, H.; Zhang, X.; Liu, M.; Hu, Z.; Fan, B. Pharm. Res. 2005, 22, 1454-1460.
• 26. Ishihama, Y.; Nakamura, M.; Miwa, T.; Kajima, T; Asakawa, N. J. Pharm. Sci. 2002, 91(4), 933-942.